Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|December 17, 2020
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitorsQiao Zhang, Taizhen Liang, Kutty Selva Nandakumar, et al.
Microbes and Infection|August 18, 2020
SNW1 interacts with IKKγ to positively regulate antiviral innate immune responses against influenza A virus infectionQiao Zhang, Taizhen Liang, Shuyin Gu, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 14, 2025
In Vitro Liquid-Liquid Phase Separation Assay for Viral ProteinsMeilin Hu, Xiaoqing Liu, Taizhen Liang, et al.
Viruses|April 28, 2023
The Involvement of Ubiquitination and SUMOylation in Retroviruses Infection and LatencyTaizhen Liang, Guojie Li, Yunfei Lu, et al.
Mbio|September 1, 2021
UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of TatTaizhen Liang, Qiao Zhang, Ziyao Wu, et al.
Cancer Science|November 2, 2021
CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancerXiaoge Niu, Wei Wang, Taizhen Liang, et al.
Biochemical Pharmacology|April 17, 2019
A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor bTaizhen Liang, Xuanxuan Zhang, Fangyuan Lai, et al.
FEBS Letters|May 27, 2018
Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelopeShuwen Yin, Xuanxuan Zhang, Fangyuan Lai, et al.
Viruses|August 26, 2023
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike ProteinTaizhen Liang, Shiqi Xiao, Ziyao Wu, et al.
Biochemical Pharmacology|September 1, 2018
PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1Jian Lin, Xuanxuan Zhang, Wanzhen Lu, et al.
Pageof 2